Nexstim Plc, a medical technology company, engages in the development of non-invasive brain stimulation technologies in Finland, rest of Europe, North America, and internationally. The company's transcranial magnetic stimulation (TMS) is a non-invasive neuromodulation technique whereby pulses of electromagnetic fields target and interact with specific brain regions from outside the head. It provides Navigated Brain Stimulation (NBS) 5 system, a TMS system for the pre-surgical mapping of the motor cortex and the speech areas of the brain; and NBS 6 and NBT, a navigated brain therapy systems for the treatment of major depressive disorder and chronic neuropathic pain. The company markets and sells its diagnostics systems to universities and teaching hospitals. It has an exclusive collaboration with Sinaptica Therapeutics, Inc. to develop, manufacture, and supply y Sinaptica's patented precision neuromodulation device based on the Nexstim NBS 6 medical TMS and neuronavigation systems and related software; and a development and distribution collaboration with Brainlab AG for the development of solutions for non-invasive mapping of specific parts of the brain and Brainlab's role as a distributor for certain Nexstim products. The company was incorporated in 2000 and is headquartered in Helsinki, Finland.